Quantum Health laid off 4% of workforce shortly after naming Dayne Williams as CEO. The company serves 3M+ members for ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Biogen is laying off staff across its research unit, marking one of the most concerted strategic decisions from Jane Grogan ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...

Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...

A biotech developing what it says is an “opioid-like” pain reliever released Phase 3 data Wednesday morning claiming the drug ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

ArriVent BioPharma, led by Bing Yao, licenses ADC MRG007 from Lepu Biopharma for $47M upfront, adding the drug to a portfolio ...

The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

Chinese biotechs Bao Pharma & Biokin file for Hong Kong listings, Disc Medicine plans $200M offering, Rivus adds $57M to Series B & Crown Labs raises Revance bid to $3.65/share ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...